Enanta Pharmaceuticals (ENTA) Operating Income Growth (5y) (2017 - 2026)

Enanta Pharmaceuticals (ENTA) Operating Income Growth (5y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Enanta Pharmaceuticals 369.97 Mn 206.20 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 16.78%
Dec 31, 2025 1.76%
Sep 30, 2025 1.45%
Jun 30, 2025 3.73%
Mar 31, 2025 -15.61%
Dec 31, 2024 -30.80%
Sep 30, 2024 -46.04%
Jun 30, 2024 -53.21%
Mar 31, 2024 -90.56%
Dec 31, 2023 -26.60%
Sep 30, 2023 -23.74%
Jun 30, 2023 -29.35%
Mar 31, 2023 -34.12%
Dec 31, 2022 -32.52%
Sep 30, 2022 -20.09%
Jun 30, 2022 -19.90%
Mar 31, 2022 -28.92%
Dec 31, 2021 -33.97%
Sep 30, 2021 -61.19%
Jun 30, 2021 -98.84%